| Issue | Title | |
| Vol 13, No 3 (2020) | Parameters for evaluating the main indicators of coloproctological care in the adult population in the subjects of the far Eastern Federal District in 2016–2018 | Abstract PDF (Rus) |
| A. V. Veselov, V. V. Omelyanosvkiy, Yu. A. Shelygin, A. V. Vitko, V. N. Kashnikov, N. V. Tashkinov, T. V. Shkurko, A. I. Moskalev, A. A. Serbina | ||
| Vol 7, No 2 (2014) | PARAMETERS OF HEALTH CARE SYSTEMS | Abstract PDF (Rus) |
| V. V. Omelyanovskiy, I. V. Maksimova, A. P. Tatarinov | ||
| Vol 11, No 4 (2018) | Patient registers and account registries of compulsory medical insurance: integration and replaceability | Abstract PDF (Rus) |
| I. A. Zheleznyakova, G. I. Pirova, E. A. Proxorovich | ||
| Vol 7, No 1 (2014) | PATIENTS WITH NEUROLOGICAL DISEASES: RATIONALE FOR PHARMACOECONOMIC EVALUATION OF COST OPTIMIZATION FOR MANAGEMENT WITH NEURON-SPECIFIC PROTEINS ASSESSMENT AS MARKERS OF INCREASED BLOOD-BRAIN-BARRIER PERMEABILITY | Abstract PDF (Rus) |
| D. V. Blinov | ||
| Vol 8, No 1 (2015) | PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION | Abstract PDF (Rus) |
| L. S. Melnikova | ||
| Vol 14, No 3 (2021) | Peculiarities of administration of medications to patients with circulatory system diseases within the framework of the federal program of preferential provision of medicines | Abstract PDF (Rus) |
| I. K. Petrukhina, R. I. Yagudina, N. V. Veyner, T. K. Ryazanova, E. P. Gladunova, V. A. Kurkin, P. R. Blinkova, E. N. Zaitseva | ||
| Vol 16, No 4 (2023) | Peculiarities of real-world data application for health technology assessment in Asian countries | Abstract PDF (Rus) |
| B. B. Kondratyeva, F. V. Gorkavenko, V. V. Omelyanovskiy | ||
| Vol 13, No 4 (2020) | Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders | Abstract PDF (Rus) |
| O. A. Gromova, I. Yu. Torshin, V. A. Maksimov, A. G. Chuchalin, V. G. Zgoda, А. N. Gromov, O. V. Tikhonova | ||
| Vol 14, No 4 (2021) | Peptides of Laennec® preparation that contribute to the elimination of endotheliopathy | Abstract PDF (Rus) |
| I. Yu. Torshin, О. А. Gromova, V. G. Zgoda, А. G. Chuchalin, V. А. Maksimov, О. V. Tikhonova | ||
| Vol 10, No 1 (2017) | PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM | Abstract PDF (Rus) |
| N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova | ||
| Vol 15, No 1 (2022) | Perioperative pharmacotherapy for endoprosthetics: potential of chondroitin sulfate and glucosamine sulfate | Abstract PDF (Rus) |
| I. Yu. Torshin, T. B. Minasov, N. V. Zagorodniy, A. M. Lila, O. A. Gromova | ||
| Vol 14, No 1 (2021) | Perspectives of osteoarthritis prevention and therapy personification based on the analysis of comorbid background, genetic polymorphisms and microelement status | Abstract PDF (Rus) |
| I. Yu. Torshin, A. M. Lila, A. V. Naumov, I. S. Sardaryan, T. E. Bogacheva, T. R. Grishina, I. V. Gogoleva, O. A. Limanova, O. A. Gromova | ||
| Vol 5, No 1 (2012) | PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION | Abstract |
| R. Yagudina, A. Kulikov, B. Misikova | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia | Abstract |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of antiretroviral therapy regimes in the Syrian Arab Republic | Abstract PDF (Rus) |
| Yu. Sh. Gushchina, А. Yu. Abramov, Y. J. Haitham | ||
| Vol 15, No 4 (2022) | Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention | Abstract PDF (Rus) |
| V. А. Ryagina, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment | Abstract |
| A. U. Kulikov, V. V. Babiy | ||
| Vol 10, No 1 (2017) | PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS | Abstract PDF (Rus) |
| A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina | ||
| Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract PDF (Rus) |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| Vol 9, No 2 (2016) | PHARMACO-ECONOMIC ANALYSIS OF COST IN TERMS OF MAINTENANCE OF PREFERENTIAL MEDICINES PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON THE TERRITORY OF KRASNOYARSK REGION | Abstract PDF (Rus) |
| T. V. Gaygolnik, I. V. Demko, E. N. Bochanova, A. Yu. Kraposhina, N. V. Gordeeva, I. A. Soloveva | ||
| Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER | Abstract |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| Vol 8, No 1 (2015) | PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION | Abstract PDF (Rus) |
| M. V. Avxentyeva, N. A. Avxentyev, M. Yu. Frolov, E. V. Derkach | ||
| Vol 13, No 4 (2020) | Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia | Abstract PDF (Rus) |
| V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract |
| R. I. Yagudina, M. M. Murashko | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract PDF (Rus) |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| Vol 17, No 4 (2024) | Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system | Abstract PDF (Rus) |
| A. V. Rudakova, I. Z. Gaydukova | ||
| Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION | Abstract |
| A. Yu. Kulikov, I. Yu. Zinchuk | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of the application of follitropin alfa in combination with assisted reproductive technologies | Abstract PDF (Rus) |
| K. A. Perova, D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, N. Z. Musina | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer | Abstract PDF (Rus) |
| O. P. Bobrova, S. K. Zyryanov, N. A. Shnayder, M. M. Petrova | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS | Abstract PDF (Rus) |
| E. E. Vidyakina, S. V. Malchikova | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation | Abstract PDF (Rus) |
| S. К. Zyryanov, I. N. Dyakov | ||
| Vol 7, No 3 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA | Abstract PDF (Rus) |
| A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova | ||
| Vol 7, No 2 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD | Abstract PDF (Rus) |
| A. S. Kolbin, I. A. Vilum, Yu. E. Balykina, M. A. Proskurin | ||
| Vol 13, No 2 (2020) | Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation | Abstract PDF (Rus) |
| S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract PDF (Rus) |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract PDF (Rus) |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract PDF (Rus) |
| A. G. Tolkushin, N. L. Pogudina | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings | Abstract PDF (Rus) |
| M. V. Zhuravleva, S. N. Avdeev, Yu. V. Gagarina, T. V. Marin | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract PDF (Rus) |
| S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer | Abstract PDF (Rus) |
| N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov | ||
| Vol 16, No 4 (2023) | Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation | Abstract PDF (Rus) |
| M. V. Zhuravleva, K. A. Kokushkin, E. A. Luchinin, E. V. Luchinina, T. R. Kameneva, E. V. Kuznetsova, V. S. Krysanova, E. V. Makarova, L. G. Zhukova | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation | Abstract PDF (Rus) |
| R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova, I. Yu. Torshin | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract PDF (Rus) |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | Abstract PDF (Rus) |
| N. A. Avxentyev, M. Yu. Frolov | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic aspects of COVID-19 treatment | Abstract PDF (Rus) |
| I. V. Rogova, E. A. Zhidkova, I. A. Popova, A. V. Zaborovskiy, K. G. Gurevich | ||
| Vol 10, No 2 (2017) | PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY | Abstract PDF (Rus) |
| A. V. Rudakova, S. A. Protsenko, I. A. Koroleva | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price | Abstract PDF (Rus) |
| D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract PDF (Rus) |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| Vol 11, No 1 (2018) | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | Abstract PDF (Rus) |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| Vol 13, No 1 (2020) | Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy | Abstract PDF (Rus) |
| S. K. Zyryanov, I. N. Diyakov | ||
| 301 - 350 of 528 Items | << < 2 3 4 5 6 7 8 9 10 11 > >> | |
Browse Title Index
Popular articles
Vol 10, No 1 (2017)
Vol 17, No 3 (2024)
Vol 16, No 3 (2023)
Vol 16, No 4 (2023)
Vol 13, No 1 (2020)
Keywords
COVID-19
NAFLD
budget impact
budget impact analysis
chemotherapy
children
chondroitin sulfate
clinical and economic analysis
cost minimization analysis
cost-effectiveness analysis
cost-utility analysis
drug supply
drugs
evidence-based medicine
glucosamine sulfate
health technology assessment
pharmacoeconomic analysis
pharmacoeconomics
pharmacoepidemiology
pharmacoinformatics
quality of life
Publisher: IRBIS LLC
24 Chechersky St., Moscow 117042
Phone: +7 (495) 649 54 95
Email: digevskaya@irbis-1.ru
